QNCX · Quince Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $32.99M | $35.38M | $18.59M | $9.45M | $25.18M | $60.8M | $61.31M | $30.21M | $10.09M | |
| $27.81M | $15.05M | $17.58M | $17.7M | $26.01M | $29.52M | $17.59M | $8.95M | $2.03M | |
| $152K | $142K | $186K | $322K | $204K | $344K | $332K | $188K | $51K | |
| $127.16M | $58.07M | $57.29M | $34.62M | $52.02M | $90.32M | $78.89M | $39.17M | $12.12M | |
| -$127.16M | -$58.07M | -$57.29M | -$34.62M | -$52.02M | -$90.32M | -$78.89M | -$39.17M | -$12.12M | |
| — | — | — | — | — | — | — | — | $957K | |
| $1.27M | $1.24M | $2.93M | $3.48M | $1.07M | $620K | $2.04M | $2.19M | $806K | |
| $2.47M | $486K | -$676K | -$102K | -$997K | -$247K | $0 | $0 | — | |
| — | -$80.77M | -$56.74M | -$31.58M | -$51.94M | -$89.95M | -$76.85M | -$36.98M | — | |
| -$2.16M | $3.21M | $87K | -$197K | -$284K | $0 | $0 | $0 | $0 | |
| -$92.48M | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -$89.95M | -$76.85M | -$36.98M | -$12.48M | |
| -$94.38M | -$78.19M | -$59.91M | -$28.05M | -$51.87M | -$90.34M | -$76.6M | -$36.87M | -$12.53M | |
| USD/shares | -$139.16 | -$336.00 | -$262.00 | -$168.00 | -$308.00 | -$606.00 | — | — | — |
| USD/shares | -$153.56 | -$336.00 | -$262.00 | -$168.00 | -$308.00 | -$606.00 | — | — | — |
| shares | — | 250.48K | 216.31K | 186.19K | 167.48K | 148.59K | 145.88K | 95.16K | 16.81K |
| shares | — | 250.48K | 216.31K | 186.19K | 167.48K | 148.59K | 145.88K | 95.16K | 16.81K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
| Current portion of long-term debt | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 270 similar-size Biotechnology companies (of 532 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$58,068,000 | -$57,285,000 | -$34,620,000 |